Tags

Type your tag names separated by a space and hit enter

Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.
Stem Cell Res Ther. 2021 03 18; 12(1):192.SC

Abstract

Over recent years, mesenchymal stem/stromal cells (MSCs) and their potential biomedical applications have received much attention from the global scientific community in an increasing manner. Firstly, MSCs were successfully isolated from human bone marrow (BM), but in the next steps, they were also extracted from other sources, mostly from the umbilical cord (UC) and adipose tissue (AT). The International Society for Cellular Therapy (ISCT) has suggested minimum criteria to identify and characterize MSCs as follows: plastic adherence, surface expression of CD73, D90, CD105 in the lack of expression of CD14, CD34, CD45, and human leucocyte antigen-DR (HLA-DR), and also the capability to differentiate to multiple cell types including adipocyte, chondrocyte, or osteoblast in vitro depends on culture conditions. However, these distinct properties, including self-renewability, multipotency, and easy accessibility are just one side of the coin; another side is their huge secretome which is comprised of hundreds of mediators, cytokines, and signaling molecules and can effectively modulate the inflammatory responses and control the infiltration process that finally leads to a regulated tissue repair/healing or regeneration process. MSC-mediated immunomodulation is a direct result of a harmonic synergy of MSC-released signaling molecules (i.e., mediators, cytokines, and chemokines), the reaction of immune cells and other target cells to those molecules, and also feedback in the MSC-molecule-target cell axis. These features make MSCs a respectable and eligible therapeutic candidate to be evaluated in immune-mediated disorders, such as graft versus host diseases (GVHD), multiple sclerosis (MS), Crohn's disease (CD), and osteoarthritis (OA), and even in immune-dysregulating infectious diseases such as the novel coronavirus disease 2019 (COVID-19). This paper discussed the therapeutic applications of MSC secretome and its biomedical aspects related to immune-mediated conditions. Sources for MSC extraction, their migration and homing properties, therapeutic molecules released by MSCs, and the pathways and molecular mechanisms possibly involved in the exceptional immunoregulatory competence of MSCs were discussed. Besides, the novel discoveries and recent findings on immunomodulatory plasticity of MSCs, clinical applications, and the methods required for their use as an effective therapeutic option in patients with immune-mediated/immune-dysregulating diseases were highlighted.

Authors+Show Affiliations

Tyumen State Medical University, Tyumen, Russian Federation.Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India.Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia.German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), 69120, Heidelberg, Germany.DigiCare Behavioral Research, Casa Grande, AZ, USA.Professor and Associate Dean for Faculty Affairs, Taneja College of Pharmacy, University of South Florida, Tampa, FL, USA.Department of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. alihassanzadeh1369@yahoo.com. Cell Therapy and Regenerative Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. alihassanzadeh1369@yahoo.com. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. alihassanzadeh1369@yahoo.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33736695

Citation

Markov, Alexander, et al. "Mesenchymal Stem/stromal Cells as a Valuable Source for the Treatment of Immune-mediated Disorders." Stem Cell Research & Therapy, vol. 12, no. 1, 2021, p. 192.
Markov A, Thangavelu L, Aravindhan S, et al. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther. 2021;12(1):192.
Markov, A., Thangavelu, L., Aravindhan, S., Zekiy, A. O., Jarahian, M., Chartrand, M. S., Pathak, Y., Marofi, F., Shamlou, S., & Hassanzadeh, A. (2021). Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Research & Therapy, 12(1), 192. https://doi.org/10.1186/s13287-021-02265-1
Markov A, et al. Mesenchymal Stem/stromal Cells as a Valuable Source for the Treatment of Immune-mediated Disorders. Stem Cell Res Ther. 2021 03 18;12(1):192. PubMed PMID: 33736695.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. AU - Markov,Alexander, AU - Thangavelu,Lakshmi, AU - Aravindhan,Surendar, AU - Zekiy,Angelina Olegovna, AU - Jarahian,Mostafa, AU - Chartrand,Max Stanley, AU - Pathak,Yashwant, AU - Marofi,Faroogh, AU - Shamlou,Somayeh, AU - Hassanzadeh,Ali, Y1 - 2021/03/18/ PY - 2020/12/26/received PY - 2021/03/02/accepted PY - 2021/3/19/entrez PY - 2021/3/20/pubmed PY - 2021/3/30/medline KW - Coronavirus disease 2019 (COVID-19) KW - Graft versus host diseases (GVHD) KW - Mesenchymal stem/stromal cells (MSCs) KW - Multiple sclerosis (MS) KW - Osteoarthritis (OA) SP - 192 EP - 192 JF - Stem cell research & therapy JO - Stem Cell Res Ther VL - 12 IS - 1 N2 - Over recent years, mesenchymal stem/stromal cells (MSCs) and their potential biomedical applications have received much attention from the global scientific community in an increasing manner. Firstly, MSCs were successfully isolated from human bone marrow (BM), but in the next steps, they were also extracted from other sources, mostly from the umbilical cord (UC) and adipose tissue (AT). The International Society for Cellular Therapy (ISCT) has suggested minimum criteria to identify and characterize MSCs as follows: plastic adherence, surface expression of CD73, D90, CD105 in the lack of expression of CD14, CD34, CD45, and human leucocyte antigen-DR (HLA-DR), and also the capability to differentiate to multiple cell types including adipocyte, chondrocyte, or osteoblast in vitro depends on culture conditions. However, these distinct properties, including self-renewability, multipotency, and easy accessibility are just one side of the coin; another side is their huge secretome which is comprised of hundreds of mediators, cytokines, and signaling molecules and can effectively modulate the inflammatory responses and control the infiltration process that finally leads to a regulated tissue repair/healing or regeneration process. MSC-mediated immunomodulation is a direct result of a harmonic synergy of MSC-released signaling molecules (i.e., mediators, cytokines, and chemokines), the reaction of immune cells and other target cells to those molecules, and also feedback in the MSC-molecule-target cell axis. These features make MSCs a respectable and eligible therapeutic candidate to be evaluated in immune-mediated disorders, such as graft versus host diseases (GVHD), multiple sclerosis (MS), Crohn's disease (CD), and osteoarthritis (OA), and even in immune-dysregulating infectious diseases such as the novel coronavirus disease 2019 (COVID-19). This paper discussed the therapeutic applications of MSC secretome and its biomedical aspects related to immune-mediated conditions. Sources for MSC extraction, their migration and homing properties, therapeutic molecules released by MSCs, and the pathways and molecular mechanisms possibly involved in the exceptional immunoregulatory competence of MSCs were discussed. Besides, the novel discoveries and recent findings on immunomodulatory plasticity of MSCs, clinical applications, and the methods required for their use as an effective therapeutic option in patients with immune-mediated/immune-dysregulating diseases were highlighted. SN - 1757-6512 UR - https://www.unboundmedicine.com/medline/citation/33736695/Mesenchymal_stem/stromal_cells_as_a_valuable_source_for_the_treatment_of_immune_mediated_disorders_ L2 - https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02265-1 DB - PRIME DP - Unbound Medicine ER -